Abstract 164P
Background
Molecularly-matched therapy (MMT) is associated with increased response rates and in some cases with improved survival. Next generation sequencing (NGS) - based multigene panels offer a wide range of analyzed markers. There is a need to optimize comprehensive profiling and find the most relevant molecular targets according to tumor type.
Methods
Retrospective analysis of NGS reports and clinical data of patients with advanced gastrointestinal tumors was performed. The frequency of detected molecular alterations in each cancer type, the frequency of MMT recommendation were assessed. Efficacy was estimated using progression-free survival (PFS) ratio (PFS2/PFS1).
Results
Between 2019 and 2023, tumor samples from 107 patients with gastrointestinal tumors were analyzed using NGS-based panels (colorectal cancer (CRC) - 64 patients (59%), pancreatic cancer (PCa) - 21 (20%), cholangiocellular cancer (CCC) - 12 (11%), gastric cancer (GC) - 11 (10%). Median age was 58 years, median number of lines before analysis - 2. MMT after NGS was administered to 17 patients (16%). Of these patients 6 samples were assesed as ESCAT I tier (35%), 2 (12%) - ESCAT IIB, 2 (12%) - ESCAT IIIA, 7 (51%) - ESCAT IIIB. PFS2/1 ratio≥1,3 was reached in 10 patients (59%). In the cohort of patients who have not been prescribed MMT, the PFS ratio was available for 42 patients, among whom 11 patients (26%) achieved PFS1/2 ≥1,3 (p=0,005). MMT was the only favorable predictor of PFS2/1 ≥1.3 (HR 0.13; 95% CI 0.03 - 0.50, p=0.003) in univariate analysis. Median overall survival in the MMT and non-MMT groups was 6 and 5 months, respectively (HR=2.07; 95% CI 1.01 - 4.26). Table: 164P
Variables | Univariate analysis | |
HR (95% CI) | p value | |
Age, years ≥60 <60 | 1,00 0,80 (0,21 -2,91) | 0,72 |
Number of lines before analysis, ≤1 ≥2 | 1,00 0,67 (0,16 - 2,86) | 0,59 |
Sex, m f | 1,60 (0,45 - 5,70) 1,00 | 0,47 |
Molecular tumor board Yes No | 1,00 0,61 (0,13 - 2,85) | 0,53 |
RAS RASwt RASmut | 1,00 (0,28 - 3,61) 1,00 | 1,00 |
MMT Yes No | 1,00 0,13 (0,03 - 0,50) | 0,003 |
Conclusions
MMT may potentially have advantages over non-MMT in advanced gastrointestinal cancers when standard therapy options are limited. In order to optimize testing in routine practice, it is necessary to create more limited panels for profiling according to each tumor type.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract